232 related articles for article (PubMed ID: 37858171)
1. Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy.
Li J; Han X; Gao S; Yan Y; Li X; Wang H
J Nanobiotechnology; 2023 Oct; 21(1):382. PubMed ID: 37858171
[TBL] [Abstract][Full Text] [Related]
2. A General Biomineralization Strategy to Synthesize Autologous Cancer Vaccines with cGAS-STING Activating Capacity for Postsurgical Immunotherapy.
Li Q; Dong Z; Cao Z; Lei H; Wang C; Hao Y; Feng L; Liu Z
ACS Nano; 2023 Jun; 17(11):10496-10510. PubMed ID: 37184402
[TBL] [Abstract][Full Text] [Related]
3. PhotoPyro-Induced cGAS-STING Pathway Activation Enhanced Anti-Melanoma Immunotherapy via a Manganese-Coordinated Nanomedicine.
Feng Y; Wang G; Li W; Yan J; Yu X; Tian H; Li B; Dai Y
Adv Healthc Mater; 2024 Mar; 13(6):e2302811. PubMed ID: 37909376
[TBL] [Abstract][Full Text] [Related]
4. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Activation of cGAS for Cancer Immunotherapy.
Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT
Front Immunol; 2021; 12():753472. PubMed ID: 34899704
[TBL] [Abstract][Full Text] [Related]
6. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
7. Manganese-Based Nanoactivator Optimizes Cancer Immunotherapy
Hou L; Tian C; Yan Y; Zhang L; Zhang H; Zhang Z
ACS Nano; 2020 Apr; 14(4):3927-3940. PubMed ID: 32298077
[TBL] [Abstract][Full Text] [Related]
8. Toll-Like Receptor (TLR) Signaling Enables Cyclic GMP-AMP Synthase (cGAS) Sensing of HIV-1 Infection in Macrophages.
Siddiqui MA; Yamashita M
mBio; 2021 Dec; 12(6):e0281721. PubMed ID: 34844429
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
10. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.
Gu Z; Hao Y; Schomann T; Ossendorp F; Ten Dijke P; Cruz LJ
J Control Release; 2023 May; 357():531-544. PubMed ID: 37030544
[TBL] [Abstract][Full Text] [Related]
11. Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy.
Iurescia S; Fioretti D; Rinaldi M
Recent Pat Anticancer Drug Discov; 2018; 13(1):2-17. PubMed ID: 29086701
[TBL] [Abstract][Full Text] [Related]
12. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
[TBL] [Abstract][Full Text] [Related]
13. Innate immunity: Looking beyond T-cells in radiation and immunotherapy combinations.
McMahon RA; D'Souza C; Neeson PJ; Siva S
Neoplasia; 2023 Dec; 46():100940. PubMed ID: 37913654
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy Based on Cell Membrane-Coated Nanocomposites Augmenting cGAS/STING Activation by Efferocytosis Blockade.
Chen Z; Li Z; Huang H; Shen G; Ren Y; Mao X; Wang L; Li Z; Wang W; Li G; Zhao B; Guo W; Hu Y
Small; 2023 Oct; 19(43):e2302758. PubMed ID: 37381095
[TBL] [Abstract][Full Text] [Related]
15. Triggering of the cGAS-STING Pathway in Human Plasmacytoid Dendritic Cells Inhibits TLR9-Mediated IFN Production.
Deb P; Dai J; Singh S; Kalyoussef E; Fitzgerald-Bocarsly P
J Immunol; 2020 Jul; 205(1):223-236. PubMed ID: 32471881
[TBL] [Abstract][Full Text] [Related]
16. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC.
Li K; Gong Y; Qiu D; Tang H; Zhang J; Yuan Z; Huang Y; Qin Y; Ye L; Yang Y
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002188
[TBL] [Abstract][Full Text] [Related]
17. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
18. Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy.
Fan Y; Gao Y; Nie L; Hou T; Dan W; Wang Z; Liu T; Wei Y; Wang Y; Liu B; Que T; Lei Y; Zeng J; Ma J; Wei W; Li L
Mol Cell; 2023 Oct; 83(19):3520-3532.e7. PubMed ID: 37802025
[TBL] [Abstract][Full Text] [Related]
19. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
20. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
